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1043-64 Adverse Outcomes in Women Undergoing 
Percutaneous Coronary Intervention
Laxmi S. Mehta, James A. Goldstein, Stephen J. Mattichak, Renato G. Ramos, Judith 
Boura, Randy Miller, Cindy L. Grines, William W. O'Neill, William Beaumont Hospital, 
Royal Oak, MI
Background: Although cardiovascular disease is the most common cause of death in
women in the United States, females are generally underrepresented in clinical trials.
This study was designed to investigate whether there are differences in baseline risk fac-
tors between genders that influence outcomes after percutaneous coronary intervention
(PCI).
Methods: We analyzed 20,870 patients from the William Beaumont Hospital Interven-
tional Database. We compared baseline characteristics and in-hospital outcomes
between women (n=6745, 32%) and men (n=14125, 68%).
Results: Women were older (68 + 11 vs 63 + 11, p<0.0001) and had a higher prevalence
of risk factors including diabetes (32% vs 25%, p<0.0001), hypertension (71% vs 61%,
p<0.0001), though not hypercholesterolemia (62.7% vs 64.5%, p=0.012). Women also
had a higher incidence of congestive heart failure (18% vs 11%, p<0.0001), chronic renal
failure (4.3% vs 3.5%, p=0.0076), stroke (11% vs 7.5%, p<0.0001) and peripheral vascu-
lar disease (17% vs 14%, p<0.0001). Importantly women were less likely to have a prior
history of angioplasty (35% vs 38%, p<0.0001) and bypass surgery (16% vs 22%,
p<0.0001). Women were more likely to be treated with balloon angioplasty alone (40% vs
36%, p<0.0001) whereas men were more likely to undergo stenting (53% vs 56%,
p=0.0043). Women suffered more in-hospital post-procedural complications including
pulmonary edema (0.4% vs 0.2%, p=0.02), renal failure (2.1% vs 1.6%, p=0.0073), reoc-
clusion (0.5% vs 0.2%, p=0.0012), retroperitoneal bleed (0.6% vs 0.1%, p<0.0001),
strokes (0.6% vs 0.3%, p=0.012), and death (2.6% vs 1.3%, p<0.0001).
Conclusions: Women undergoing PCI have more high-risk cardiovascular characteris-
tics and have a higher incidence of in-hospital adverse outcomes compared to men.
1043-65 Simple Risk Score Predicts Myocardial Infarction and 
Cardiovascular Death at 30 Days After Percutaneous 
Coronary Intervention: An Analysis of the REPLACE-2 
and TARGET Data
David G. Burger, Gang Jia, Neal S. Kleiman, Baylor College of Medicine, Houston, TX
Background:A reliable way to predict the risk of death or myocardial infarction (MI) after
Percutaneous Coronary Intervention (PCI) in the era of glycoprotein IIb/IIIa inhibitors and
stent use has been elusive. Using a multivariable logistic regression model in a large PCI
trial database, we developed and tested a cumulative risk score to predict likelihood of MI
or Cardiovascular (CV) death 30 days after PCI. Methods: Univariate analysis of base-
line, angiographic, procedural data points were associated with the endpoints of MI or
(CV) death at 30 days as determined by the clinical endpoints committee for the
REPLACE - 2 trial. Variables with statistical significance (p<0.05) were then tested in a
multivariate logistic regression model as predictors for the same endpoints. From this
model four of the statistically significant variables were then assigned a value of 1 if
present in each patient. These variables included LVEF <35%, > 2 lesions attempted,
AHA/ACC lesion score B2 or C, and any stent deployment. Each patient was then
assigned a cumulative score of 0 to 4 based on the presence of these four variables.
Patient groups defined by their cumulative score were then correlated with the risk of MI
and CV death at 30 days. This same risk score was then applied to the TARGET data
using slightly modified variables to account for differences in acquired data points.
Results: There was a near linear correlation between cumulative risk score and the end-
points of MI and CV death. For the REPLACE – 2 data risk score stratification of
0,1,2,3,and 4 correlated with endpoint rates of 2.07, 4.14, 6.89, 11.38, and 9.80%
respectively (p<0.001). Risk score stratification of the TARGET data yielded similar
results with cumulative risk score groups 0,1,2,3,and 4 associated with endpoint rates of
1.10, 4.01, 7.80, 10.61, and 16.67 % respectively (p<0.001). The C statistic for the risk
score in REPLACE2 is 0.622, and is 0.613 when tested in TARGET. Conclusions: A sim-
ple cumulative risk using four easily accessible variables can help predict the probability
of MI and cardiovascular death at 30 days.
1043-66 Procedural Predictors of Creatine Kinase-MB Elevations 
in the REPLACE-2 Study
Kirk Gavlick, James C. Blankenship, Neal S. Kleiman, John A. Bittl, Frederick Feit, Eric J. 
Topol, A. Michael Lincoff, Geisinger Medical Center, Danville, PA, Cleveland Clinic 
Foundation, Cleveland, OH
BACKGROUND: Angiographic complications (AC) of percutaneous coronary interven-
tion (PCI) predict creatine kinase – MB (CK-MB) elevation after PCI and are decreased
by intravenous 2b/3a inhibitors. We analyzed data from REPLACE-2 to determine if simi-
lar results were obtained with bivalirudin.
METHODS: In REPLACE-2, 6010 patients were randomized to bivalirudin versus hep-
arin plus eptifibatide or abciximab during PCI. AC were recorded by operators at the time
of PCI. CK-MB was measured at 8 hour intervals after PCI.
RESULTS: Angiographic complications occurred in 10.3% of patients, including 11% in
bivalirudin-treated patients and 9.5% in heparin-2b/3a patients (p = 0.053). All 13 catego-
ries of AC occurred with similar frequency in both groups. These included decreased flow
during PCI, severe dissection , new thrombus, distal embolization, unplanned stenting,
side branch occlusion, abrupt closure, and prolonged ischemia of any cause (p > 0.25 for
each).
CK-MB > 3 x normal occurred in 7.5% of patients and was similar for both treatment
arms. CK-MB > 3 x normal occurred with increased frequency in patients with AC com-
pared to those without (22.9% vs 3.7%, RR = 4.0, p < 0.001). Of 13 AC types, 11 were
predictive of CK-MB > 3 x normal including distal embolization (relative risk (RR) 14, p <
0.001), side branch occlusion (RR = 13, p < 0.01), any cause of prolonged ischemia (RR
= 13, p < 0.01), and transient slow flow (RR 8, p < 0.01). However, of 388 patients with
CK-MB > 3 x normal, 265 (68%) had angiographiclly uncomplicated, successful proce-
dures.
CONCLUSIONS: Bivalirudin is as effective as heparin with 2b/3a inhibitors in preventing
AC during PCI. The occurrence of AC entails a four-fold risk of CK-MB > 3 times normal
after PCI. However, CK-MB > 3 x normal occurs in 5.7% of patients whose PCI is angio-
graphically uncomplicated, and 2/3 of all CK-MB elevations occur after uncomplicated
PCI. Routine CK-MB enzyme monitoring after PCI is still necessary, since selective CK-
MB enzyme monitoring only after AC occur would miss many CK-MB elevations.
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1044-51 PeriStent Restenosis Following Drug-Eluting Stents: 
Influence of Contributing Factors
David O. Williams, David Snead, Jeffrey J. Popma, Rhode Island Hospital, Providence, 
RI
Background: In the SIRIUS trial the effectiveness of sirolimus-eluting stents was dimin-
ished by re-stenosis at stent margins, particularly at the proximal site.
Methods: To better understand this finding we sought to identify factors associated with
peri-stent restenosis using the clinical, angiographic and intravascular ultrasound (IVUS)
databases of the SIRIUS trial. Patients within the SIRIUS trial with angiographic and
IVUS baseline and follow-up evaluations formed the study cohort.
Results: There was no significant relationship between stent to lesion ratio (SLR) and
binary peri-stent restenosis rate by univariate analysis. Regression relationships were
developed comparing SLR to proximal margin late loss (mm), distal margin late loss
(mm) by quantitative angiography and by IVUS determined follow-up proximal and distal
margin plaque volumes (mm3) and follow-up proximal and distal margin minimal lumen
diameters (mm). None of these analyses revealed a significant relationship between SLR
and any of the outcome variables for either sirolimus-treated or bare stent patients.
Univariate analysis of sirolimus treated patients demonstrated a significant (p<0.05)
association between proximal/distal restenosis rate (peri-stent restenosis) at 8 months
and post-procedure in-stent minimal lumen diameter (OR 0.23, p<0.002), pre-procedure
reference vessel diameter (OR 0.32, p<0.004), post-procedure reference vessel diameter
(OR 0.32, p<0.006) history of diabetes (OR 2.3, p<0.01) and cigarette smoking within the
past year (OR 2.1, p<0.03). Factors associated with proximal/distal restenosis by multi-
variate modeling included post-procedure minimal lumen diameter (OR 0.23, p<0.002),
cigarette smoking during the past year (OR 2.3, p<0.02) and history of diabetes (OR 2.1,
p<0.03).
Conclusions: Peri-stent restenosis was related to smaller vessel diameter and the his-
tory of diabetes or recent cigarette smoking. We did not detect a relationship between
SLR and peri-stent restenosis. These findings could influence the technique for utilizing
drug-eluting stents. Caution is advised, however, in interpreting these results given the
low event rate of peri-stent restenosis.
